MiNA Therapeutics
96 Kensington High Street
London
W8 4SG
United Kingdom
Website: http://minatx.com/
Email: info@minatx.com
49 articles about MiNA Therapeutics
-
NS Pharma Announces Research Alliance with MiNA Therapeutics to Develop Therapies for Rare Diseases of the Central Nervous System
4/4/2024
NS Pharma, Inc. (NS Pharma) announced that its parent company, Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) – headquartered in Kyoto, Japan, entered into a joint research agreement with MiNA Therapeutics – headquartered in London, United Kingdom, to develop nucleic acid drugs for the potential treatment of intractable and rare diseases of the central nervous system.
-
MiNA Therapeutics Enters Research Collaboration with Nippon Shinyaku to Develop RNAa Therapeutics Targeting Rare Neurodegenerative Diseases
4/4/2024
MiNA Therapeutics today announced a research collaboration and licensing agreement option with Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters: Kyoto; President: Toru Nakai), an innovation-driven Japanese-based pharmaceutical company focused on disease areas of high unmet medical need.
-
MiNA Therapeutics Presents New Data for its HbF Program at the Keystone Symposia’s Delivery of Nucleic Acid Therapeutics Conference
1/24/2024
MiNA Therapeutics Limited announced today that it will present new pre-clinical data for its lead RNA activation program targeting fetal hemoglobin (HbF) at the Keystone Symposia’s Delivery of Nucleic Acid Therapeutics Conference in Banff, Alberta, Canada.
-
MiNA Therapeutics Highlights Preclinical Research on RNA Activation (RNAa) Therapeutics Presented at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting
10/25/2023
MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, highlights preclinical research presented by academic partners at the annual meeting of the Oligonucleotide Therapeutics Society (OTS) in Barcelona, Spain.
-
MiNA Therapeutics Enters Research Collaboration with BioMarin Pharmaceutical to Advance RNAa Platform Research in Rare Genetic Diseases
4/25/2023
MiNA Therapeutics today announced a multi-target research collaboration and option licensing agreement with BioMarin Pharmaceutical Inc.
-
MiNA Therapeutics Presents Proof of Mechanism Data on MTL-STING as a Novel Cancer Immunotherapy
4/11/2022
MTL-STING is the second drug candidate to be advanced from the Company’s internal pipeline of small activating RNA therapeutics STING is a highly validated drug target that plays a key role in immune evasion in cancer MiNA Therapeutics Limited, the pioneer in small activating RNA therapeutics, presents preclinical proof of mechanism data on MTL‑STING as a novel cancer immunotherapy.
-
First Patient Dosed in Randomised Phase 2 Clinical Trial of MTL-CEBPA in Patients with Advanced Liver Cancer
1/25/2022
MiNA Therapeutics Limited, the pioneer in small activating RNA therapeutics, announces that it has dosed the first patient in a global Phase 2 clinical trial of MTL-CEBPA in combination with second line standard of care sorafenib ) in advanced hepatocellular carcinoma.
-
MiNA Therapeutics Appoints Two Independent Directors With Extensive Industry Experience to Support Next Phase of Growth
12/21/2021
MiNA Therapeutics Limited, the pioneer in small activating RNA therapeutics, announces the expansion of its Board, with the appointment of Susan Clement-Davies and Professor Sir Robert Lechler as Independent Directors, effective 1 January 2022.
-
National University Cancer Institute, Singapore and MiNA Therapeutics Announce Initiation of a Phase 1 Clinical Study of MTL-CEBPA in Combination With First-line Standard of Care in Advanced Liver Cancer
12/1/2021
The National University Cancer Institute, Singapore and MiNA Therapeutics Limited announce that the first patient has been dosed in an investigator-sponsored Phase 1 study of MiNA’s small activating RNA oligonucleotide, MTL-CEBPA, in combination with first-line standard of care, atezolizumab and bevacizumab, in patients with previously untreated, advanced hepatocellular carcinoma.
-
MiNA Therapeutics to present at Jefferies 2021 London Healthcare Conference
11/12/2021
MiNA Therapeutics Limited, the pioneer in small activating RNA therapeutics, announces that its Chief Executive Officer, Robert Habib, will present and host one-on-one meetings at the Jefferies 2021 London Healthcare Conference, taking place from 16-19 November 2021 in-person and virtually.
-
MiNA Therapeutics Highlights Clinical Data Supporting the Further Development of MTL-CEBPA as an Anti-cancer Immunotherapy
11/12/2021
MiNA Therapeutics Limited, the pioneer in small activating RNA therapeutics, announces positive safety data from the Phase 1a/b TIMEPOINT study of MTL-CEBPA in combination with pembrolizumab in adult patients with advanced solid tumours.
-
MiNA Therapeutics Expands Senior Leadership Team With Four New Hires to Support Next Phase of Growth
10/12/2021
MiNA Therapeutics Limited, the pioneer in small activating RNA therapeutics, announces that it has significantly expanded its senior leadership team with four new appointments to support the Company’s next phase of growth.
-
MiNA Therapeutics Announces Equity Investment From Lilly
7/6/2021
MiNA Therapeutics Limited, the pioneer in small activating RNA therapeutics, announces that Eli Lilly and Company has entered into a definitive agreement under which it will make a direct equity investment in MiNA.
-
Lilly and MiNA Therapeutics Announce saRNA Research Collaboration
5/11/2021
Eli Lilly and Company and MiNA Therapeutics Limited, a pioneer in RNA activation therapeutics, announced a global research collaboration to develop novel drug candidates using MiNA's proprietary small activating RNA technology platform.
-
Eli Lilly announced a drug development collaboration with MiNA Therapeutics Limited focusing on five novel drug candidates that could be worth up to $245 million.
-
MiNA Therapeutics Presents Translational Data at AACR Supporting MTL-CEBPA as Immunological Cancer Combination Treatment
4/9/2021
MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced translational data supporting the favourable immunological effects of MTL-CEBPA and its benefits in combination with other cancer therapies including anti-PD1 checkpoint inhibition.
-
Data on multiple oncology therapeutic programs are being unveiled ahead of the start of the annual American Association for Cancer Research meeting, which will be held virtually this year due to the ongoing COVID-19 pandemic.
-
Servier and MiNA Therapeutics Enter Collaboration in Neurological Diseases
1/21/2021
MiNA eligible for up to 220 M€ in upfront, development and commercial milestone payments for first target.
-
Servier and MiNA Therapeutics are partnering on small activating RNA (saRNA) therapies to treat neurological diseases. saRNA is an entirely new class of drugs.
-
BioSpace Movers & Shakers, Jan. 8
1/8/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.